In a recent InvestorIntel interview, Tracy Weslosky spoke with David Regan, CEO ofSona Nanotech Inc.(CSE: SONA | OTCQB: SNANF) abouttheir rapid saliva COVID-19 test and about why Sona Nanotech is the gold standard for nanotechnology. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), David Regan said that Sona Nanotech has developed a unique biocompatible gold nanorod technology that has a wide variety of medical applications. Highlighting the absence of a rapid saliva covid-19 test in the market, David went on to provide an update on Sona Nanotechs partnership with US FDA registered Arlington Scientific to bring Sonas rapid saliva COVID-19 test to market. David also provided an update on the appointment of two directors to Sona Nanotechs board with backgrounds with a NASDAQ-listed biotech company and Medtronic Canada. To watch the full interview,click here. About Sona Nanotech Inc. Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotechs gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sonas gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA. To learn more about Sona Nanotech Inc.,click here. SubscribeEmail address is invalidThank you for joining InvestorIntel daily email updates Disclaimer:Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp. This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the Company being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete. This presentation may contain forward-looking statements within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Companys business or any investment therein. Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Companys financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Companys profile onSedar.comand to carry out independent investigations in order to determine their interest in investing in the Company. If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct atinfo@investorintel.com. - For more visit [ Ссылка ]

свернуть